Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01311687
What this trial is testing

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Who this might be right for
Multiple Myeloma
Celgene 455
Testing effectiveness (Phase 2)Ended earlyNCT01672736
What this trial is testing

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
University Health Network, Toronto 19
Testing effectiveness (Phase 2)Study completedNCT01794039
What this trial is testing

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 9
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)Looking for participantsNCT07096778
What this trial is testing

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma RefractoryMultiple Myeloma in Relapse
CellCentric Ltd. 100
Large-scale testing (Phase 3)Study completedNCT03275285
What this trial is testing

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 302
Testing effectiveness (Phase 2)UnknownNCT04287855
What this trial is testing

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Poitiers University Hospital 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT04850599
What this trial is testing

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
OHSU Knight Cancer Institute 5
Testing effectiveness (Phase 2)UnknownNCT04674514
What this trial is testing

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Ascentage Pharma Group Inc. 48
Testing effectiveness (Phase 2)UnknownNCT00003885
What this trial is testing

Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Our Lady of Mercy Medical Center 60
Testing effectiveness (Phase 2)Study completedNCT01166113
What this trial is testing

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 67
Early research (Phase 1)Looking for participantsNCT06348108
What this trial is testing

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Alfred Chung, MD 32
Early research (Phase 1)Looking for participantsNCT07444268
What this trial is testing

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Who this might be right for
Advanced Hematologic Malignancies
Sumitomo Pharma America, Inc. 8
Testing effectiveness (Phase 2)Study completedNCT02612779
What this trial is testing

Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 74
Testing effectiveness (Phase 2)Looking for participantsNCT06232096
What this trial is testing

MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd. 154
Not applicableStudy completedNCT03188536
What this trial is testing

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Who this might be right for
Multiple Myeloma
Takeda 282
Testing effectiveness (Phase 2)WithdrawnNCT05408026
What this trial is testing

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Early research (Phase 1)Study completedNCT01727778
What this trial is testing

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Drug Safety
Patrys Ltd. 12
Testing effectiveness (Phase 2)Study completedNCT00402181
What this trial is testing

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Centocor, Inc. 53
Early research (Phase 1)Active Not RecruitingNCT06223516
What this trial is testing

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 60
Next Page